Fleischmann, R., Friedman, A., Drescher, E., Singhal, A., Cortes-Maisonet, G., Doan, T., . . . Blanco, R. (2022). Safety and efficacy of elsubrutinib or upadacitinib alone or in combination (ABBV-599) in patients with rheumatoid arthritis and inadequate response or intolerance to biological therapies: A multicentre, double-blind, randomised, controlled, phase 2 trial. Elsevier.
Citace podle Chicago (17th ed.)Fleischmann, R., et al. Safety and Efficacy of Elsubrutinib or Upadacitinib Alone or in Combination (ABBV-599) in Patients with Rheumatoid Arthritis and Inadequate Response or Intolerance to Biological Therapies: A Multicentre, Double-blind, Randomised, Controlled, Phase 2 Trial. Elsevier, 2022.
Citace podle MLA (9th ed.)Fleischmann, R., et al. Safety and Efficacy of Elsubrutinib or Upadacitinib Alone or in Combination (ABBV-599) in Patients with Rheumatoid Arthritis and Inadequate Response or Intolerance to Biological Therapies: A Multicentre, Double-blind, Randomised, Controlled, Phase 2 Trial. Elsevier, 2022.